Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-Dose vs Standard-Dose Caspofungin for Invasive Candidiasis
NCT00250432Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jan 2006
- Primary completion
- Jan 2008
- Modality
- Cyclic Peptides, Antimicrobial Peptides, Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of caspofungin in invasive candidiasis (2 arms), sponsored by Merck & Co. Primary endpoint: Number of Patients Who Develop Significant Drug-related Adverse Events at 90 days. Started Jan 2006; status: completed.
02
Drugs
caspofungin
03
Conditions
invasive candidiasis
Beyond the preview
Go deeper on NCT00250432.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00250432.